Epidiolex® (CBD) Treatment Outcomes, Safety, and Real-world Evidence
Monday, December 6, 2021
-
You may need to log in to view video on this page.
OVERVIEW:
Inform HCPs and other stakeholders of the most recent safety and efficacy data on Epidiolex® (CBD) , from primary and secondary analyses; practical clinical management information; and real-world treatment outcomes.
Exhibitor: Greenwich Biosciences, Inc.
Activity Type
Scientific Exhibit
Credit
Non-CME
Format
In person
Career Stage
Early Career (typically 0-5 years from completion of training)
Mid-Career (typically 6-15 years from completion of training)
Senior (typically >15 years from completion of training)
Audience
Behavioral Health Providers
Clinicians
Fellows/Trainees
Nurses
Scientists/Researchers
Advanced Practice Providers
Advocates
Pharmacists
Technicians
Demographic
Clinical
First-time Attendees
Research
Young Professionals